FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 783 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR After a Generous Donor Covered Her Bills, Breast Cancer Survivor Raises... December 22, 2020 FDA Approves Lorlatinib for Metastatic ALK-positive Non-Small Cell Lung Cancer March 10, 2021 Cancer in My Community: How People With Cancer Access Care in... August 12, 2021 Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention... April 29, 2025 Load more HOT NEWS Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced... Teacher Reads To Students One Day After Having Brain Surgery TP53 Allelic State is Critical in Myelodysplastic Syndromes Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation...
